Transcatheter arterial and venous embolisation with α-hexyl cyanoacrylate MagicGlue®: short-term safety and efficacy outcomes.

Purpose: Our purpose was to assess the feasibility and the short-term safety and efficacy outcomes of a wide range of transcatheter arterial and venous embolisation procedures done using α-hexyl-cyanoacrylate (AHCA)-MagicGlue® in patients with bleeding and non-bleeding disorders.

Methods: This single-centre retrospective study included consecutive patients who underwent emergent or planned AHCA-MagicGlue® transcatheter embolisation between February 2019 and September 2023. Technical success, clinical success, 30-day mortality, and complication rates were evaluated.

Results: We included 101 patients with a mean age of 49.9 ± 20.5 years who underwent arterial (n = 43, 42.6%) or venous (n = 58, 57.4%) embolisation for bleeding (n = 16, 15.8%) or other reasons (n = 85, 84.2%). The technical success rate was 100%. After a mean follow-up of 2.2 months, the clinical success rate was 94% in patients with bleeding and 95% in other patients; 1 patient died of multi-organ failure unrelated to the procedure. In the 22 patients with prostatic artery embolisation, statistically significant improvements were recorded at 3 months versus baseline for the International Prostate Symptoms Score (IPSS) (10.0 ± 5.8 vs. 20.8 ± 7.3, p = 0.001), IPSS quality-of-life score (2.0 ± 1.4 vs. 5.0 ± 1.0; p = 0.001), and prostate volume (67.8 ± 38.0 mL vs. 96.7 ± 47.4 mL, p = 0.001). Adverse events occurred in 11 (10.9%) patients and were major in 4 and minor in 7 patients.

Conclusions: MagicGlue® transcatheter arterial and venous embolisation is feasible, effective, and safe for bleeding and non-bleeding conditions across a broad range of anatomic sites.